Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is a life-threatening treatment-related toxicity that limits...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2020-02, Vol.38 (5), p.415-422
Hauptverfasser:	Frey, Noelle V, Shaw, Pamela A, Hexner, Elizabeth O, Pequignot, Edward, Gill, Saar, Luger, Selina M, Mangan, James K, Loren, Alison W, Perl, Alexander E, Maude, Shannon L, Grupp, Stephan A, Shah, Nirav N, Gilmore, Joan, Lacey, Simon F, Melenhorst, Jos J, Levine, Bruce L, June, Carl H, Porter, David L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Age Factors Aged Female Humans Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Male Middle Aged ORIGINAL REPORTS Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Receptors, Antigen, T-Cell - therapeutic use Survival Rate Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!